Daniel Pollyea

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

June, 2025

Daniel Pollyea

Dec 10, 2024, 18:55 | Insight

Joshua Zeidner: The prognostic influence of monocytic phenotypes in patients treated with Azacitidine and Venetoclax

Joshua Zeidner, Associate Professor at UNC Lineberger, shared on X: “Fantastic presentation by Curtis Lachowiez…

Nov 6, 2024, 16:47 | Insight

Curtis Lachowiez: Refining risk prediction for HMA and venetoclax-based treatment in AML

Curtis Lachowiez, Assistant Professor of Medicine at Oregon Health and Science University, shared a post…

Aug 19, 2024, 10:07 | Insight

Nicolas Duployez: A 4-gene prognostic model stratified OS outcomes with VEN-AZA treatment in AML

Nicolas Duployez, Molecular Biologist at Lille University Hospital, shared on X about a recent paper…

May 12, 2024, 01:40 | Insight

Justin Watts: A significant portion of patients at the extremes of older age (80-90) still derive benefit from the VEN-HMA regimen

Justin Watts et al. report that standard of care treatment for acute myeloid leukemia extends…

All: 4 Posts: 1 - 100

'

BEATcc Trial at ESMOGynaec25: Atezolizumab Benefits Cervical Cancer Patients Regardless of PD-L1 Status

'

15 Posts Not to Miss from EACR 2025

'

ASCO 2025 RCC Advances: Expert Insights by Ilya Tsimafeyeu

'

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

'

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023